Science

Oncotarget: Australian experience of peptide receptor radionuclide therapy

Oncotarget: Australian experience of peptide receptor radionuclide therapy

Oncotarget Volume 11, Issue 27 published “Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours” by Lim et al. which reported peptide receptor radionuclide therapy (PRRT) is an approved treatment modality for gastroenteropancreatic neuroendocrine tumours, although Phase III randomised clinical trial data is not available for NETs of other site of origin, in practice, PRRT is used more widely in clinical practice, based on its mechanism of targeting the somatostatin receptor.

Read More…….
EurekAlert!, the online, global news service operated by AAAS, the science society,